Larazotide acetate alters the paracellular permeability of the GI tract to inhibit transport of gluten peptides into the lamina propria, according to the report. When compared to a placebo, the primary results of the outcome were reduced symptoms of diarrhea, indigestion and abdominal pain as measured by the Celiac Disease Gastrointestinal Symptom Rating Scale.
If approved by the FDA, the drug would not be a solo treatment, but rather a complementary strategy alongside current dietary strategies.
More articles on gastroenterology:
6 gastroenterologists making headlines
Solos Endoscopy to expand device distribution to Canada
Does sigmoidoscopy fill a colorectal cancer screening niche?
